Physician profile
Jeffrey Hamby
NPI 1831178524
$8,303.12
in general payments reported to CMS, 2019-2025
38 companies · $569 in 2025
The $569 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $613 · 2020: $4,422 · 2021: $692 · 2022: $971 · 2023: $626 · 2024: $410 · 2025: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,605.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $3,774.84 | 2019-2020 | |
| Abbvie INC. | $1,049.65 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $598.60 | 2020-2025 | Caplyta |
| Astrazeneca Pharmaceuticals Lp | $508.48 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Sunovion Pharmaceuticals INC. | $506.90 | 2019-2022 | |
| Lilly USA, LLC | $197.66 | 2020-2023 | Mounjaro |
| Amgen INC. | $194.31 | 2020-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $161.84 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $131.70 | 2021-2024 | |
| Glaxosmithkline, LLC. | $131.42 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $130.17 | 2019-2020 | |
| Pfizer INC. | $101.55 | 2020-2025 | |
| Otsuka America Pharmaceutical, INC. | $85.11 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $83.95 | 2020-2022 | |
| Corium, LLC | $62.82 | 2022-2025 | Azstarys |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Hamby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.